Work

Epigenetic Therapy for Friedreich’s Ataxia: a Phase 1, First in Man, Ascending Dose Crossover Study to Investigate the Safety, Pharmacokinetics and Pharmacodynamics of Rg2833 (a Histone Deacetylase Inhibitor) in Adults With Friedreich’s Ataxia